The so-called 'dementia epidemic' is thought to be as a result of our changing demographic profile with regard to longer lives. Diseases of old age such as Alzheimer's are set to dominate and the burden placed on individuals, families and health-care systems cannot be underestimated. This is all compounded by the as-yet lack of any great medical breakthrough in treatment and diagnostics.
My question is could/should the insurance industry be supporting research into novel pharmaceutical treatments?
Category: Funding longer lives: Health/medicine